Effects of Internet Cognitive-Behavioral Therapy on Depressive Symptoms and Surrogates of Cardiovascular Risk in Human Immunodeficiency Virus: A Pilot, Randomized, Controlled Trial
Open Access
- 1 July 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 7 (7), ofaa280
- https://doi.org/10.1093/ofid/ofaa280
Abstract
Background. Depression is associated with an increased risk of cardiovascular disease in human immunodeficiency virus (HIV). We hypothesized that reducing depressive symptoms would improve HIV-related cardiovascular risk. Methods. We conducted a single-center, randomized (1:1), controlled, parallel-group, assessor-blinded, pilot trial comparing Beating the Blues US (BtB)-an evidence-based, 8-session, internet cognitive-behavioral therapy for depression-with usual care (UC) in HIV-positive participants receiving virologically suppressive antiretroviral therapy and with Patient Health Questionnaire (PHQ)-9 scores >= 10. The primary endpoint was change in brachial artery flow-mediated dilation (FMD) at 12 weeks. Secondary endpoints were FMD change at 24 weeks and inflammation, coagulation, and metabolic biomarker changes at 12 and 24 weeks. Results. Fifty-four participants were randomized (27 in each arm). Mean reductions in PHQ-9 scores were significantly greater with BtB versus UC at 12 weeks (-5.60 vs -1.52; P = .007) and 24 weeks (-6.00 vs -1.38; P = .008); reductions in the Hopkins Symptom Checklist Depression Scale-20 scores were also significantly greater with BtB versus UC at 24 weeks (-0.72 vs -0.35; P = .029). Changes in FMD between arms were not significantly different at 12 or 24 weeks. Significantly larger reductions in soluble (s)CD14 and sCD163 with BtB versus UC were found at 12 and 24 weeks, respectively. Conclusions. Compared with UC, internet cognitive-behavioral therapy using BtB resulted in greater improvements in depressive symptoms and monocyte activation markers but did not improve FMD in this pilot trial. These data support performing larger studies to determine the potential salutatory effects of behavioral therapies for depression on HIV-related inflammation.Funding Information
- National Heart, Lung, and Blood Institute (R01HL126557)
- National Center for Advancing Translational Sciences (UL1TR002529)
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097512)
This publication has 35 references indexed in Scilit:
- Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studiesBMC Psychiatry, 2014
- Effect of Collaborative Care for Depression on Risk of Cardiovascular EventsPsychosomatic Medicine, 2014
- Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected IndividualsPLOS ONE, 2012
- HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte ActivationClinical Infectious Diseases, 2012
- Depressed Mood and Flow-Mediated DilationPsychosomatic Medicine, 2011
- Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-AnalysisPsychosomatic Medicine, 2009
- Depression and the risk for cardiovascular diseases: systematic review and meta analysisInternational Journal of Geriatric Psychiatry, 2007
- Cytokines sing the blues: inflammation and the pathogenesis of depressionTrends in Immunology, 2006
- Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy womenPsychoneuroendocrinology, 2004
- The Relation of Severity of Depressive Symptoms to Monocyte-Associated Proinflammatory Cytokines and Chemokines in Apparently Healthy MenPsychosomatic Medicine, 2003